Literature DB >> 18320151

Advances in the diagnosis and immunotherapy for ocular inflammatory disease.

Steven Yeh1, Lisa J Faia, Robert B Nussenblatt.   

Abstract

Significant advances in the diagnosis and therapy for uveitis have been made to improve the quality of care for patients with ocular inflammatory diseases. While traditional ophthalmic examination techniques, fluorescein angiography, and optical coherence tomography continue to play a major role in the evaluation of patients with uveitis, the advent of spectral domain optical coherence tomography and fundus autofluorescence into clinical practice provides additional information about disease processes. Polymerase chain reaction and cytokine diagnostics have also continued to play a greater role in the evaluation of patients with inflammatory diseases. The biologic agents, a group of medications that targets cytokines and other soluble mediators of inflammation, have demonstrated promise in targeted immunotherapy for specific uveitic entities. Their ophthalmic indications have continued to expand, improving the therapeutic armentarium of uveitis specialists.

Entities:  

Mesh:

Year:  2008        PMID: 18320151     DOI: 10.1007/s00281-008-0109-4

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  175 in total

Review 1.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Authors:  D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

2.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  Adalimumab: a new modality for Behçet's disease?

Authors:  J A M van Laar; T Missotten; P L A van Daele; A Jamnitski; G S Baarsma; P M van Hagen
Journal:  Ann Rheum Dis       Date:  2006-11-23       Impact factor: 19.103

4.  Tuberculous uveitis: distribution of Mycobacterium tuberculosis in the retinal pigment epithelium.

Authors:  Narsing A Rao; Sindhu Saraswathy; Ronald E Smith
Journal:  Arch Ophthalmol       Date:  2006-12

5.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

6.  A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.

Authors:  Craig L Leonardi; Darryl Toth; Jennifer C Cather; Richard G B Langley; Winifred Werther; Peter Compton; Paul Kwon; Graham Wetherill; Francois Curtin; Alan Menter
Journal:  Dermatology       Date:  2006       Impact factor: 5.366

7.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

8.  Serum cytokine receptor levels in noninfectious uveitis.

Authors:  Necip Torun; Josep Callizo; Natasa Orlic; Matthias Scherer; Christian Hartmann; Uwe Pleyer
Journal:  Ophthalmic Res       Date:  2005-03-03       Impact factor: 2.892

9.  Monitoring herpesvirus DNA in three cases of acute retinal necrosis by real-time PCR.

Authors:  Shinya Asano; Tetsushi Yoshikawa; Hiroshi Kimura; Yoshihiko Enomoto; Masahiro Ohashi; Hiroko Terasaki; Yukihiro Nishiyama
Journal:  J Clin Virol       Date:  2004-03       Impact factor: 3.168

10.  Triple agent immunosuppression in serpiginous choroiditis.

Authors:  P L Hooper; H J Kaplan
Journal:  Ophthalmology       Date:  1991-06       Impact factor: 12.079

View more
  8 in total

1.  Development of an activity disease score in patients with uveitis (UVEDAI).

Authors:  Esperanza Pato; Mª Auxiliadora Martin-Martinez; Adela Castelló; Rosalía Méndez-Fernandez; Santiago Muñoz-Fernández; Miguel Cordero-Coma; Lucia Martinez-Costa; Elia Valls; Miguel Reyes; Félix Francisco; Mar Esteban; Alex Fonollosa; Fernando Sanchez-Alonso; Cruz Fernández-Espartero; Teresa Diaz-Valle; José Miguel Carrasco; Emma Beltran-Catalán; Marisa Hernández-Garfella; María Victoria Hernández; Laura Pelegrin; Ricardo Blanco; David Diaz-Valle
Journal:  Rheumatol Int       Date:  2016-11-04       Impact factor: 2.631

Review 2.  Diagnostic vitrectomy for primary intraocular lymphoma: when, why, how?

Authors:  Cindy S Hwang; Steven Yeh; Chris S Bergstrom
Journal:  Int Ophthalmol Clin       Date:  2014

3.  A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis.

Authors:  Grazyna Adamus; Landon J Karren; Jeff Mooney; Gregory G Burrows
Journal:  Ophthalmic Res       Date:  2010-02-08       Impact factor: 2.892

4.  Efficacy of adalimumab for pediatric Vogt-Koyanagi-Harada syndrome.

Authors:  Abdallah Jeroudi; Sheila T Angeles-Han; Steven Yeh
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2014 Jul-Aug       Impact factor: 1.300

5.  Adalimumab for pediatric sympathetic ophthalmia.

Authors:  Joon-Bom Kim; Abdallah Jeroudi; Sheila T Angeles-Han; Hans E Grossniklaus; Steven Yeh
Journal:  JAMA Ophthalmol       Date:  2014-08       Impact factor: 7.389

Review 6.  Fundus autofluorescence applications in retinal imaging.

Authors:  Andrea Gabai; Daniele Veritti; Paolo Lanzetta
Journal:  Indian J Ophthalmol       Date:  2015-05       Impact factor: 1.848

7.  Local therapies for inflammatory eye disease in translation: past, present and future.

Authors:  Shenzhen Tempest-Roe; Lavnish Joshi; Andrew D Dick; Simon R J Taylor
Journal:  BMC Ophthalmol       Date:  2013-08-06       Impact factor: 2.209

Review 8.  Role of autofluorescence in inflammatory/infective diseases of the retina and choroid.

Authors:  Ahmed Samy; Sue Lightman; Filis Ismetova; Lazha Talat; Oren Tomkins-Netzer
Journal:  J Ophthalmol       Date:  2014-04-01       Impact factor: 1.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.